- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Particle density.
Displaying page 1 of 1.
EudraCT Number: 2015-001934-19 | Sponsor Protocol Number: LPS14354 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Sanofi-Aventis Groupe | |||||||||||||
Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002090-23 | Sponsor Protocol Number: K-111-2.02EU | Start Date*: 2005-02-03 |
Sponsor Name:Kowa Research Europe Ltd. | ||
Full Title: A phase IIa multicentre randomised double-blind, double-dummy study to evaluate the efficacy and safety of K-111 versus Fenofibrate in patients with hyperlipidaemia. | ||
Medical condition: Hyperlipidaemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000799-92 | Sponsor Protocol Number: LPS14355 | Start Date*: 2015-12-31 | |||||||||||
Sponsor Name:sanofi-aventis Groupe | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hyperchole... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002315-17 | Sponsor Protocol Number: MGL-3196-06 | Start Date*: 2017-01-12 | |||||||||||
Sponsor Name:Madrigal Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia | |||||||||||||
Medical condition: Heterozygous Familial Hypercholesterolemia (HeFH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000065-16 | Sponsor Protocol Number: DS102A-07-CV1 | Start Date*: 2020-08-11 | ||||||||||||||||
Sponsor Name:Afimmune Ltd. | ||||||||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab... | ||||||||||||||||||
Medical condition: Hypertriglyceridemia and Type 2 Diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) LV (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003249-16 | Sponsor Protocol Number: PML_DOC_1102 | Start Date*: 2012-01-06 | |||||||||||
Sponsor Name:University Hospital of Antwerp | |||||||||||||
Full Title: OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN AS... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005447-25 | Sponsor Protocol Number: INTIMA | Start Date*: 2013-02-22 | |||||||||||
Sponsor Name:Academic Medical Center Amsterdam, department of Internal Medicine | |||||||||||||
Full Title: The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque | |||||||||||||
Medical condition: Atherosclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002315-25 | Sponsor Protocol Number: TAK-475/EC303 | Start Date*: 2005-12-15 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezet... | |||||||||||||
Medical condition: Treatment of patients with primary dyslipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) EE (Completed) FI (Completed) LV (Completed) LT (Completed) HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002278-30 | Sponsor Protocol Number: APH-19 | Start Date*: 2020-08-12 | |||||||||||
Sponsor Name:Amryt Pharmaceuticals DAC | |||||||||||||
Full Title: Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) o... | |||||||||||||
Medical condition: Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European populat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003840-22 | Sponsor Protocol Number: D6160C00048 | Start Date*: 2005-06-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Double-blind, Multi-centre, Active-Controlled (15, 30, and 45mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar (0.5 and 1 mg) in Patients wit... | |||||||||||||
Medical condition: Type II Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000437-13 | Sponsor Protocol Number: R1500-HTG-20118 | Start Date*: 2022-01-07 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis | |||||||||||||
Medical condition: Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010520-25 | Sponsor Protocol Number: AMR-01-01-0016 | Start Date*: 2009-12-08 | ||||||||||||||||
Sponsor Name:Amarin Pharma Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglycer... | ||||||||||||||||||
Medical condition: Hypertriglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) DK (Prematurely Ended) FI (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001261-40 | Sponsor Protocol Number: I2R-MC-BIAN | Start Date*: 2012-03-05 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I2R-MC-BIAN (a) Study: The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: an Open-Label, Randomized, 78 w... | |||||||||||||
Medical condition: Type 1 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
